Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
06 October 1995Website:
http://myriad.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
MYGN Latest News
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said it's a Great Place To Work – 27 percentage points higher than the average U.S. company.
New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad's breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test. RiskScore combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick model, a widely used breast cancer risk assessment calculator.
VENLO, The Netherlands and SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS) test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer and is expected to enhance decentralized testing capacities once a regulated product is developed with pharmaceutical partners. The project builds on the recently announced master collaboration agreement between the two companies.
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators
The positive initial study results from Myriad Genetics (MYGN) are expected to enhance clinical outcomes and lower healthcare expenses.
Investors are hopeful about Myriad Genetics' (MYGN) solid financial position and increase in testing volume.
Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.
Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.
Myriad Genetics, Inc. (MYGN) Q4 2023 Earnings Call Transcript
What type of business is Myriad Genetics?
Myriad Genetics, Inc. is one of the largest specialized molecular diagnostic laboratories in the world. Founded in 1992, the headquarters is located in Salt Lake City, Utah. The company uses a range of patented technologies, including DNA, RNA, and protein analysis, to help understand the genetic basis of human diseases and the role that genes and their associated proteins may play in the onset and progression of disease. The company uses this information to guide the development of new molecular diagnostic and companion diagnostic tests designed to assess individual risk of developing disease in old age, determine the likelihood of a patient's response to drug therapy and dosage for the patient, or assess the risk of disease progression and recurrence.
What sector is Myriad Genetics in?
Myriad Genetics is in the Healthcare sector
What industry is Myriad Genetics in?
Myriad Genetics is in the Diagnostics & Research industry
What country is Myriad Genetics from?
Myriad Genetics is headquartered in United States
When did Myriad Genetics go public?
Myriad Genetics initial public offering (IPO) was on 06 October 1995
What is Myriad Genetics website?
https://myriad.com
Is Myriad Genetics in the S&P 500?
No, Myriad Genetics is not included in the S&P 500 index
Is Myriad Genetics in the NASDAQ 100?
No, Myriad Genetics is not included in the NASDAQ 100 index
Is Myriad Genetics in the Dow Jones?
No, Myriad Genetics is not included in the Dow Jones index
When does Myriad Genetics report earnings?
The next expected earnings date for Myriad Genetics is 02 August 2024